ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).

A. Nejad, A. Vo, J. Choi, S. Jordan.

Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.

Meeting: 2016 American Transplant Congress

Abstract number: A113

Keywords: Highly-sensitized, Infection, IVIG, Kidney transplantation

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: Kidney Desensitization

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
  • Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab

INTRODUCTION: IVIG has become an essential tool in the treatment of sensitized patients prior to solid organ transplantation and is routinely used to treat viral infections in the transplant patient population. IVIG is prepared from the plasma of donors carefully screened for HIV, Hepatitis A, B, and C. Donors are screened for Hepatitis B with nucleic acid amplification technologies as well as screening for hepatitis B surface antigen. Hepatitis B core antibody positivity alone is not an exclusion criteria for donation and the passive transfer of Hepatitis B core antibodies has been documented. Our aim is to better determine the frequency of passive transfer of Hepatitis B core antibodies in order to prevent misdiagnosis and unnecessary treatment in the post-transplant period. METHODS: Monitoring of Hepatitis B serologies is done routinely in our sensitized patient population awaiting renal transplantation. Hepatitis B serologies are obtained in all patients prior to desensitization, during the desensitization period, and following transplantation. Hepatitis B serologies were reviewed for all patients who underwent renal transplantation between January 1st and April 30th 2015. RESULTS: 27 sensitized patients underwent pre-transplant immunomodulation and renal transplantation between January 1st and April 30th 2015. Of these 27 patients, 7 patients were found to have at least one positive Hepatitis B core antibody serology. Of these 7 patients, only 1 had documented Hepatitis B core antibody positivity prior to undergoing desensitization (immune due to natural infection). The remaining 6 appear to have developed positive serologic testing through the passive transfer of antibodies following IVIG administration. CONCLUSIONS: Hepatitis B core positivity is of significant clinical significance in patients preparing to undergo solid organ transplantation. Patients with true Hepatitis B core positivity prior to transplantation are often treated with nucleoside reverse transcriptase inhibitors post transplant with careful evaluation of liver function. Although repeat hepatitis B serologies are necessary to confirm return to negative serologic status, 22% of patients appear to have developed Hepatitis B core antibody positivity secondary to treatment with IVIG. It is thus important for clinicians to be aware that the passive transfer of Hepatitis B core antibody may be relatively common and should be considered before initiating treatment or excluding such patients from study trial entry.

CITATION INFORMATION: Nejad A, Vo A, Choi J, Jordan S. Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES). Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nejad A, Vo A, Choi J, Jordan S. Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES). [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/transient-hepatitis-b-core-positivity-after-administration-of-ivig-for-desensitization-des/. Accessed January 22, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
    • Penis Transplantation: First U.S. Experience.
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
    • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.